Heparins and heparinoids: Occurrence, structure and mechanism of antithrombotic and hemorrhagic activities

Current Pharmaceutical Design

Volumn 10, Issue 9, 2004, Pages 951-966

  Nader, Helena B ^a   Lopes, Carla C ^a   Rocha, Hugo A O ^a   Santos, Elizeu A ^a   Dietrich, Carl P ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anticloting and hemorrhagic activity; Antithrombotic activity; Antithrombotic activity and mechanism of action; Antithrombotic agents and vascular endothelial cells; Antithrombotic heparan sulfate and fucans; Heparin; Heparins; LMW heparins and heparinoids; Occurrence and structural variability

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTICOAGULANT AGENT; APROSULATE; ARDEPARIN; CHONDROITIN SULFATE; CY 222; DALTEPARIN; DERMATAN SULFATE; DEXTRAN SULFATE; ENOXAPARIN; FUCOIDIN; GLUCURONIC ACID; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; HEPARINOID; IDURONIC ACID; LACTOBIONIC ACID; LOW MOLECULAR WEIGHT HEPARIN; LW 10282; NADROPARIN; OP 386; PARNAPARIN; PENTASACCHARIDE; POLYSACCHARIDE; PROTAMINE; SERINE PROTEINASE; SULEPAROIDE; SULFAMINOHEPAROSAN; TINZAPARIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALGA; ANTICOAGULATION; ARTERY THROMBOSIS; BLEEDING; CLINICAL TRIAL; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PANCREAS; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HEPARINOIDS; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOSIS;

EID: 1642373288     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043452758     Document Type: Review

References (90)

1. National Vital Statistics Reports 2003; 51: 4-9.
2. McLean J. The discovery of heparin. Circulation 1959; 19: 75-8.
3. Silva ME, Dietrich CP. The structure of heparin Characterization of the products formed from heparin be the action of a heparinase and a heparitinase from Flavobacterium heparinum. J Biol Chem 1975; 250: 6841-6.
4. Cassaro CMF, Dietrich CP. Distribution of sulfated mucopolysaccharides in invertebrates. J Biol Chem 1977; 252: 2254-61.
5. Toledo OMS, Dietrich CP. Tissue specific distribution of sulfated mucopolysaccharides in mammals. Biochim Biophys Acta 1977; 498: 114-22.
6. Barlow GH, Coen LJ, Mozen MM. A biological chemical physical comparison of heparin from different, mammalian species. Biochim Biophys Acta 1964; 83: 272-7.
7. Hashimoto K, Matsuno M, Yosizawa Z, Shibata T. A dextrorotatory polysaccharide of very high anticoagulant activity newly isolated from the whale's lung intestine. Tohoku J Exp Med 1963; 81: 93-5.
8. Nader HB, Takahashi HK, Straus AH, Dietrich CP. Selective distribution of heparin in mammals: conspicuous presence of heparin in lymphoid tissues. Biochim Biophys Acta 1980; 627: 40-8.
9. Medeiros GF, Mendes A, Castro RAB, Baú EC, Nader HB, Dietrich CP. Distribution of sulfated glycosaminoglycans in the animal kingdom: widespread occurrence of heparin-like compounds in invertebrates. Biochim Biophys Acta 2000; 1475: 287-294.
10. Cavalcante MCM, Allodi S, Valente AP, Straus AH, Takahashi HK, Mourao PA S, et, al Occurrence of heparin in the invertebrate Styela plicata (Tunicata) is restricted to cell layers facing the outside environment - An ancient role in defense? J Biol Chem 2000; 275: 36189-96.
11. Burson SL., Fahrenbach MJ, Frommhagen LH, Riccardi BA, Brown RA, Brockman JA, et al. Isolation purification of mactins heparin-like anticoagulants from mollusca. J Amer Chem Soc 1956; 78: 5874-8.
12. Rahemtulla F, Løvtrup S. The comparative biochemistry of invertebrate mucopolysaccharides-V Mollusca. Comp Biochem Physiol B 1976; 53: 15-8.
13. Ehlich P. Beiträge zur Kenntnis der granulierten Bindegewebszellen und der eosinophilen Leukocythen. Arch Anat Physiol 1879: 166-9.
14. Holmgren H, Willander O. Beitrag zur Kenntnis der Chemie und Funktion der Ehrlichschen Mastzellen. Z Mikrosk Anat Forsch 1937; 42: 242-78.
15. Jorpes E, Holmgren H, Willander O. Ueber das Vorkommen von Heparin in den Gefässwänden und in den Augen Ein Beitrag zur Physiologie der Ehrlichschen Mastzellen. Z Mikrosk Anat Forsch 1937; 42: 279-301.
16. Jaques LB, Debnath AK. Simultaneous evaluation of tissue heparin mast cells in small tissue samples. Am J Physiol 1970; 219: 1155-60
17. Nader HB, Straus AH, Takahashi HK, Dietrich CP. Selective appearance of heparin in mammalian tissues during development. Biochim Biophys Acta 1982; 714: 292-297.
18. Csaba G, Toro I, Modo K. The behaviour of the thymus in conditions associated with tissue proliferation. Acta Anatom 1962; 48: 114-21.
19. Ginsburg H, Lagunoff D. The "in vitro" differentiation of mast cells. J Cell Biol 1967; 48: 685-97.
20. Ishizaka T, Okudaira H, Mauser LE, Ishizaka K. Development of rat mast cells "in vitro" I- Differentiation of mast cells from thymus cells. J Immunol 1976; 116: 747-754.
21. Burnet FM. The probable relationship of some or all mast cells to the T-cell system. Cell Immunol 1977; 30: 358-60.
22. Selye H. The mast cells. 1965; Butterworth Washington D C.
23. Straus AH, Nader HB, Dietrich CP. Absence of heparin or heparin like compounds in mast cell-free tissues animals. Biochim Biophys Acta 1982; 717: 478-85.
24. Keller R, Hess, MW, Riley, JF. Mast cells in the skin of normal hairless athymic mice. Experientia 1979; 32: 171-2.
25. Wlodarski K. Mast cells in the pinna of Balb/c "nude" (nu/nu) heterozygotes (nu/+) mice. Experientia 1976; 32: 1591-2.
26. V their increase by bone marrow transplantation. Blood 1978; 52: 447-52.
27. d anemic mice, Blood 1979; 53: 492-7.
28. Marshall JS, Kawabori S, Nielsen L, Bienenstock J. Morphological functional-characteristics of peritoneal mast-cells from young-rats. Cell Tissue Res 1994; 276: 565-570.
29. Pejler G, Berg L. Regulation of rat mast-cell protease-1 activity -protease inhibition is prevented by heparin proteoglycan. Eur J Biochem 1995; 233: 192-9.
30. Amihai D, Trachtenberg S, Terkel J, Hammel I. The structure of mast cell secretory granules in the blind mole rat (Spalax ehrenbergi). J Struct Biol 2001; 136: 96-100.
31. Dunn TB, Potter MJ. A transplantable mast-cell neoplasm in the mouse. J Natl Cancer Inst 1957; 18: 587-601.
32. Furth J, Hagen P, Hirsch EI. Transplantable mastocytoma in the mouse containing histamine heparin 5-hydroxy- triptamine. Proc Soc Exptl Biol Med 1957; 95 : 824-28.
33. 4 endogenous heparin by a microsomal fraction from mast cell tumors. J Biol Chem 1967; 242: 2301-5.
34. Lindahl U. Enzymes involved in the formation of the carbohydrate structure of heparin. Meth Enzymol 1972; 28: 676-84 Academic Press. New York.
35. Nader HB, Marx W, Spolter L. Glycosaminoglycans of some mouse mastocytomas. Biochim Biophys Acta 1980; 631: 463-78.
36. Dietrich CP, Paiva JF, Moraes CT, Takahashi HK, Porcionatto MA, Nader HB. Isolation characterization of a heparin with high anticoagulant activity from Anomalocardia brasiliana. Biochim Biophys Acta 1985; 843: 1-7.
37. Enerbäck L, Kolset SO, Kusche M, Hjerpe A, Lindahl U. Glycosaminoglycans in ral mucosal mast-cells. Biochem J 1985; 227: 661-8.
38. Nader HB, Dietrich CP. Natural occurrence possible biological role of heparin in Heparin: Chemical Biological Properties Clinical Applications (Lane DA, Lindahl U. eds.) Edward Arnold Publishers. 1989; London pp81-96.
39. Santos EA. Heparina do molusco, Anomalocardia brasiliana: A. Natureza dos resíduos de ácidos urônicos. B. Distribuição em tecidos e correlação com mastócitos. Tese de Doutorado; 1997. Escola Paulista de Medicina São Paulo SP, Brazil.
40. Santos EA , Menezes LR, Pereira NML, Andrade GPV, Nader HB, Dietrich CP. Mast cells are present in epithelial layers of different tissues of the mollusk Anomalocardia brasiliana "In situ" characterization of heparin a correlation of heparin histamine concentration. Histochem J; 2003 (in press).
41. Jaques LB. Heparins- Anionic Polyelectrolyte Drugs. Pharmacol Rev 1980; 31: 99-166.
42. Casu B, Guerrini M, Naggi A, Torri G, De-Ambrosi L, Boveri G, et al. Characterization of sulfation patterns of beef pig mucosal heparins by nuclear magnetic resonance spectroscopy. Arzneimittelforschung 1996; 46: 472-7.
43. HB Nader, CP Dietrich. Extraction characterization of heparins In Analytical techniques to evaluate the structure function of natural polysaccharides glycosaminoglycans. Ed Nicola Volpi. Research Sign Post 2002; 23-9.
44. Nader HB, Porcionatto MA, Moraes CT, Dietrich CP. Purification substrate specificity of heparinase heparitinase I heparitinase II from Flavobacterium heparinum. J Biol Chem 1990; 265: 6807-13.
45. Nader HB, Chavante SF, Santos EA, Oliveira FW, Paiva JF, Jerônimo SMB, et al. Heparan sulfates heparins: similar compounds performing the same functions in vertebrates invertebrates? Brazil J Med Biol Res 1999; 32: 529-38.
46. Dietrich CP, Paiva JF, Castro RAB, Chavante SF, Jeske W, Fareed J, et al. Structural features anticloting activities of a novel natural low molecular weight heparin from the shrimp Penaeus brasiliensis. Biochim Biophys Acta 1999; 1428: 273-83.
47. Lindahl U, Backstrom G, Thunberg L, Leder IG. Evidence for a 3-O sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin Proc Natl Acad Sci USA 1980; 77: 6551-5.
48. Olson ST, Bjork I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions - resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267: 12528-38.
49. Casu B, Lindahl U. Structure biological interactions of heparin heparan sulfate. Adv Carbohyd Chem Biochem 2001; 57: 159-206.
50. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure-activity relationship in heparin - a synthetic pentasaccharide with high-affinity for anti-thrombin-iii eliciting high anti-factor-xa activity. Biochem Biophys Res Commun. 1983; 116: 492-9.
51. Nader HB, McDuffie NM, Dietrich CP. Heparin fractionation by electrofocusing: Presence of 21 components of different molecular weights. Biochem Biophys Res Commun 1974; 57: 488-93.
52. McDuffie NM, Nader HB, Dietrich CP. Electrophocusing of heparin. Fractionation of heparin into 21 components distinguishable from other acidic mucopolysaccharides Biopolymers 1975; 14: 1473-86.
53. Dietrich CP, Nader HB, McDuffie NM. Electrophocusing of heparin Presence of 21 monomeric dimeric molecular species in heparin preparations. An Acad Brasil Ci 1975; 47: 301-9.
54. Dietrich CP, Shinjo SK, Moraes FA, Castro RAB, Mendes A, Nader HB. Structural features bleeding activity of commercial LMW-heparins: Neutralization by ATP protamine. Sem Thromb Hemost 1999; 25: 43-50.
55. Pejler G, Danielsson A, Bjork I, Lindahl U, Dietrich CP, Nader HB. Structure antithrombin-binding properties of heparin isolated from the clams Anomalocardia brasiliana and Tivela mactroides. J Biol Chem 1987; 262: 1413-21.
56. Dietrich CP, Nader HB, Paiva JF, Tersariol ILS, Santos EA, Holme KR, et al. Heparin in molluscs: Chemical enzymatic degradation 13C 1H nmr spectroscopical evidences for the maintainance of the structure through evolution. Int J Biol Macromol 1989; 11: 361-366.
57. Lindahl U, Thunberg L, Backstrom G, Riesenfeld J, Nordling K, Bjork I. Extension structural variability of the antithrombin-binding sequence in heparin. J Biol Chem 1984; 259: 12368-76.
58. Walenga JM, Jeske WP, Samama MM, Frapaise FX, Bick RL, Fareed J. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Exp Opin Invest Drugs 2002; 11: 397-407.
59. Casu B, Grazioli G, Razi N, Guerrini M, Naggi A, Torri G, et al. Heparin-like compounds prepared by chemical modification of capsular polysaccharide from Escherichia coli K5. Carbohyd Res 1994; 263: 271-84.
60. Naggi A, Torri G, Casu B, Oreste P, Zoppetti G, Li JP, et al. Toward a biotechnological heparin through combined chemical enzymatic modification of the Escherichia coli K5 polysaccharide. Semin Thromb Hemost 2001; 27: 437-43.
61. Wu SJ, Chun MW, Shin KH, Toida T, Park Y, Linhardt RJ, et al. Chemical sulfonation anticoagulant activity of acharan sulfate. Thromb Res 1998; 92: 273-81.
62. Bianchini P, Osima B, Parma B, Nader HB, Dietrich CP. Lack of correlation between "in vitro" "in vivo" antithrombotic activity of heparin fractions related compounds: Heparan sulfate as an antithrombotic agent "in vivo". Thromb Res 1985; 40: 597-607.
63. Bianchini P, Osima B, Parma B, Dietrich CP, Takahashi HK, Nader HB. Structural studies "in vivo" "in vitro" pharmacological activities of heparin fractions fragments prepared by chemical enzymic depolimerization. Thromb Res 1985; 40: 49-58.
64. Dietrich CP, Nader HB, Straus AH. Structural diferences of heparan sulfates according to the tissue and species of origin. Biochem Biophys Res Commun 1983; 111: 865 -71.
65. Dietrich CP, Tersariol ILS, Toma L, Moraes CT, Porcionatto MA, Oliveira FW, Nader HB. Sequencing of heparan sulfate: Identification of variable and constant oligosaccharide regions in eight heparan sulfates from different origins Cell Molecul Biol 1998; 44: 417-29.
66. Colburn P, Buonassisi V. Anti-clotting activity of endothelial cell cultures heparan sulfate proteoglycans. Biochem Biophys Res Commun 1982; 104: 220-227.
67. Nader HB, Dietrich CP, Buonassisi V, Colburn P. Heparin sequences in the heparan sulfate chains of an endothelial cell proteoglycan. Proc Natl Acad Sci USA 1987; 84: 3565-69.
68. Buonassisi V, Venter JC. Hormone neurotransmitter receptors in an established vascular endothelial cell line. Proc Natl Acad Sci USA 1976; 73: 1612-16.
69. Nader HB, Buonassisi V, Colburn P, Dietrich CP. Heparin stimulates the synthesis modifies the sulfation pattern of heparan sulfate proteoglycan from endothelial cells Physiol 140: 305-310.
70. Pinhal MAS, Santos IAN, Silva IF, Dietrich CP, Nader HB. Stimulation of the synthesis of an antithrombotic heparan sulfate from endothelial cells by heparin its fragments. Thrombosis Haemostasis 1995; 74: 1169-1174.
71. Pinhal MAS, Walenga JM, Jeske W, Hoppensteadt D, Dietrich CP, Fareed J, et al. Antithrombotic agents stimulate the synthesis modify the sulfation pattern of a heparan sulfate proteoglycan from endothelial cells. Thromb Res 1994; 74: 143-153.
72. Nader HB, Pinhal MAS, Baú EC, Castro RAB, Medeiros GF, Chavante SF, et al. Development of new heparin-like compounds other antithrombotic drugs and their interaction with vascular endothelial cells. Brazil J Med Biol Res 2001; 34: 699-709.
73. Bagge L, Wahlberg T, Holmer E, Tydén H, Nyström SO, Malm T. Low-molecular-weight heparin (Fragmin) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery using a pig model. Blood Coagul Fibrinol 1994; 5: 265-272.
74. Colwell CW Jr. Recent advances in the use of low molecular weight heparins as prophylaxis for deep vein thrombosis. Orthopedics 1994; 17: 5-7.
75. Haas S, Flosbach CW. Prevention of postoperative thromboembolism with Enoxaparin in general surgery: a German multicenter trial. Sem Thromb Hemost 1993; 19: 164-173.
76. Hirsh J. Comparison of the relative efficacy safety of low molecular weight heparin unfractionated heparin for the treatment of venous thrombosis. Haemostasis 1996; 26: 189-198.
77. Martineau P, Tawil N. Low-molecular-weight heparins in the treatment of deep-vein thrombosis. Ann Pharmacother 1998; 32: 588-598.
78. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low-molecular-weight heparins: pharmacologic profile product differentiation. Amer J Cardiol 1998; 82: 3L-10L.
79. Pinhal MAS, Trindade E, Fareed J, Dietrich CP, Nader HB. Heparin and a cyclic octaphenol-octasulfonic acid (GL-522-Y-1) bind with high affinity to a 47KDa protein from vascular endothelial cell surface and stimulate the synthesis and structural changes of an antithrombotic heparan sulfate. Thromb Res 2001, 103: 35-45.
80. Cruz WO. The significance of a smooth muscle component in hemostasis. Proc Soc Exptl Biol Med 1965; 119: 876-883.
81. Cruz WO, Dietrich CP. Antihemostatic effect of heparin counteracted by adenosine triphosphate. Proc Soc Exptl Biol Med 1967; 126: 420-426.
82. Nader HB, Dietrich CP. Effect of heparitin Sulfate fractions on hemostasis Proc Soc Exptl Biol Med 1974; 146: 504-508.
83. Nader HB, Tersariol ILS, Dietrich CP. Antihemostatic activity of heparin disaccharides oligosaccharides obtained by chemical enzymatic fragmentation: Reversal of the hemorrhagic activity by ATP myosin Thromb Res 1989; 54: 207-214.
84. Tersariol ILS, Dietrich CP, Nader HB. Uncoupling of actomyosin ATPase by heparin its fragments Eur J Biochem 1997; 245: 40-46.
85. Dietrich CP, Tersariol ILS, Silva RG, Bianchini P, Nader HB. Dependence of the C-6 sulfate of the glucosamine moiety and 1-4 glycosidic linkage of heparin disaccharides for production of hemorrhage. Reversal of the antihemostatic activity of heparin their fragments by ATP and myosin. Sem Thromb Hemost 1991; 17: 65-73.
86. Garcia-Jr HV, Buffolo E, Nader HB, Dietrich CP. Reduction of blood loss produced by heparin after topical application of adenosine triphosphate in cardiopulmonary by-pass operations. Ann Thorac Surg 1994; 57: 956-959.
87. Nader HB, Tersariol ILS, Dietrich CP. Structural requirements of heparin disaccharides responsible for hemorrhage: Reversion of the antihemostatic effect by ATP. FASEB J 1989; 3: 2420-24.
88. Basser R. The impact of thrombopoietin on clinical practice. Curr Pharm Design 2002; 8(5): 369-77.
89. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Design 2002; 8(19): 1765-80.
90. MacDonald KP, Hill GR. Keratinocyte Growth Factor (KGF) in hemato-logy and oncology. Curr Pharm Design 2002; 8(5): 395-03.